David Lemus

CIK: 0001717972

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

SLN

Silence Therapeutics plc

Director

SCLX

Scilex Holding Co

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

SLN
Silence Therapeutics plc
Jan 2, 2026
Award(A)
Share Option (Right to Buy)
Direct
90K shares-
SLN
Silence Therapeutics plc
Jan 2, 2025
Award(A)
Share Option (Right to Buy)
Direct
48K shares-
SCLX
Scilex Holding Co
Oct 17, 2024
Purchase(P)
Direct
2K shares at avg. $0.90$2K

		Type	Shares	Price		Ownership
Jan 2, 2026	SLN Silence Therapeutics plc	Award(A) Share Option (Right to Buy)	90,000	-	-	Direct
Jan 2, 2025	SLN Silence Therapeutics plc	Award(A) Share Option (Right to Buy)	48,000	-	-	Direct
Oct 17, 2024	SCLX Scilex Holding Co	Purchase(P)	2,000	$0.90	$1,800	Direct

1-3 of 3 transactions

About Lemus David

Lemus David (SEC CIK 0001717972) files insider reports with the SEC as Director of Silence Therapeutics plc (SLN) and Director of Scilex Holding Co (SCLX).

Signal8 holds 4 ownership filings by Lemus David (1 Form 3, 3 Form 4), filed between Oct 18, 2024 and Jan 6, 2026. Those filings report 3 transactions, from Oct 17, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lemus David's filings is in LONDON, X0.

Recent filings by Lemus David

Jan 2, 2026: Grant or award of SLN derivative securities (Form 4, code A).
Jan 2, 2025: Grant or award of SLN derivative securities (Form 4, code A).
Oct 17, 2024: Open-market purchase of SCLX shares (Form 4, code P).

Other insiders filing for Silence Therapeutics plc (SLN)

Griffiths Richard Ian, 10% Owner
Ede-Golightly James, Director
MCINERNEY TIMOTHY, Director
Romano Steven J., EVP and Chief R&D Officer
HELLUMS RHONDA LYNETTE, Chief Financial Officer
Ross Iain, Director

How to read Form 4 transaction codes